End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.622 EUR | -.--% | -.--% | -.--% |
14/05 | Anglo shareholder welcomes proposed strategic revamp | RE |
14/05 | AEGON A.M. SAYS REVAMP APPEARS TO GIVE INVESTORS "A MARKED SIMPL… | RE |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company appears to be poorly valued given its net asset value.
- This company will be of major interest to investors in search of a high dividend stock.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Life & Health Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 1.17TCr | - | ||
+13.16% | 7.95TCr | B- | ||
+10.59% | 5.21TCr | B+ | ||
+6.04% | 4.9TCr | B | ||
+21.41% | 4.67TCr | B+ | ||
+15.32% | 4.27TCr | B+ | ||
+28.76% | 4.14TCr | B | ||
+0.65% | 2.95TCr | B | ||
-3.35% | 2.91TCr | B- | ||
-9.40% | 2.73TCr | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AGN Stock
- 1AGN Stock
- Ratings Aegon Ltd.